We've put some small files called cookies on your device to make our site work.
We'd also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.
Let us know if this is OK. We'll use a cookie to save your choice. You can read more about our cookies before you choose.
Clinical Commissioning Policy: Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above)
This policy document outlines the arrangements for funding of treatment for refractory focal onset seizures, associated with tuberous sclerosis complex, for ages 2 years and above.
Document
Clinical Commissioning Policy: Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above)
